Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide therapy for renal cell carcinoma.

Robert J Amato1

  • 1Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, 77030, Houston, TX, USA. ramato@bcm.tmc.edu

Critical Reviews in Oncology/Hematology
|July 10, 2003
PubMed
Summary

Thalidomide shows activity in metastatic renal cell carcinoma (RCC), with 40-45% of patients benefiting. Further research into thalidomide combinations is necessary to optimize its use in RCC treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation and Clinical Applications of a Comprehensive Next Generation Sequencing System for Molecular Characterization of Solid Cancer Tissues.

Frontiers in molecular biosciences·2019
Same author

Klotho inhibits EGF-induced cell migration in Caki-1 cells through inactivation of EGFR and p38 MAPK signaling pathways.

Oncotarget·2018
Same author

CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression.

Oncotarget·2014
Same author

Clinical outcomes model in renal cell cancer patients treated with modified vaccinia Ankara plus tumor-associated antigen 5T4.

The International journal of biological markers·2014
Same author

Folate receptor-β constitutes a marker for human proinflammatory monocytes.

Journal of leukocyte biology·2014
Same author

A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2014

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) presents a significant therapeutic challenge.
  • Identifying novel treatment strategies for advanced RCC is crucial.

Purpose of the Study:

  • To review the efficacy and safety of thalidomide in metastatic RCC.
  • To assess thalidomide's role as a monotherapy and in combination regimens.

Main Methods:

  • Systematic review of phase II studies evaluating thalidomide alone or with immunotherapy/chemotherapy.
  • Assessment of clinical benefit based on objective response and stable disease rates.

Main Results:

  • Single-agent thalidomide yielded partial responses in a median of 7% and stable disease in 31% of patients.
  • Overall, 40-45% of patients showed benefit from thalidomide, with common toxicities including constipation, lethargy, and neuropathy.
  • Combination studies with interleukin-2 (IL-2) and interferon (IFN) showed promise, despite some toxicity concerns.

Conclusions:

  • Thalidomide demonstrates activity in metastatic RCC.
  • Further investigation into thalidomide-based combinations is required to establish its optimal role in RCC management.

Related Experiment Videos